Indication Strategy

Our initial target indications in clinical development are Clinical High Risk for Psychosis and patients suffering from Insomnia Disorder, using our CBD micelle formulation.

In addition, we are in pre-clinical development for General Anxiety Disorder (GAD), Restless Legs Syndrome (RLS) and Post-Traumatic Stress Disorder (PTSD).


Drug Pipeline

Having completed pre-clinical & formulation work with the University of Toronto, we will go into Phase 2 A/B for Insomnia Disorder and Phase 3 for Clinically High Risk (CHR) for Psychosis, starting in 2023.


Why CBD as a lead molecule? - Efficacious, safe and ready for re-formulation

Efficacious for a range of indications

  • CBD has a network of actions on many receptors, pathways and systems in the body, including the endocannabinoid system (one of the key homeostatic regulatory systems of the body)
  • Potential for a wide range of indications:brain functioning, psychiatry, sleep, pain, mood, inflammation, oxidation and the immune system
  • Millions of people are using CBD for sleep (although with sub-optimal formulation and dosing)
    CBD has been shown to be neuroprotective and effective for treatment and prevention of psychosis


  • CBD displays a markedly superior side-effect profile to existing medications, and it has been found to be safe